Anterogen: 1Q26 Sales Up 32%, Japan Approval for ALLO-ASC-EB

1Q26 sales reached KRW 2.12bn (vs KRW 1.60bn YoY, +32%), operating loss maintained at KRW 1.10bn
ALLO-ASC-EB for epidermolysis bullosa received Japanese PMDA manufacturing and sales approval in April 2026
Cash & equivalents KRW 1.68bn, short-term financial assets KRW 41.0bn, total KRW 42.7bn; net debt negative (debt-free)
R&D expenses KRW 1.30bn (61% of sales), net loss KRW 0.88bn (vs KRW 0.70bn), total comprehensive loss KRW 3.62bn (equity valuation loss)
Trade receivables KRW 2.49bn, allowance for bad debts KRW 5mn (0.2%); no contingent liabilities or litigation